

# Journal Pre-proof

Impact of COVID-19 on national surveillance of norovirus in England and potential risk of increased disease activity in 2021

Amy Douglas, Frank G. Sandmann, David J. Allen, Cristina C. Celma, Stuart Beard, Lesley Larkin



PII: S0195-6701(21)00101-8

DOI: <https://doi.org/10.1016/j.jhin.2021.03.006>

Reference: YJHIN 6338

To appear in: *Journal of Hospital Infection*

Received Date: 6 March 2021

Accepted Date: 6 March 2021

Please cite this article as: Douglas A, Sandmann FG, Allen DJ, Celma CC, Beard S, Larkin L, Impact of COVID-19 on national surveillance of norovirus in England and potential risk of increased disease activity in 2021, *Journal of Hospital Infection*, <https://doi.org/10.1016/j.jhin.2021.03.006>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2021 Published by Elsevier Ltd on behalf of The Healthcare Infection Society.

**Title:** Impact of COVID-19 on national surveillance of norovirus in England and potential risk of increased disease activity in 2021

**Authors:** Amy Douglas <sup>1</sup>, Frank G Sandmann <sup>2,3</sup>, David J Allen <sup>4</sup>, Cristina C Celma<sup>5</sup>, Stuart Beard<sup>5</sup> and Lesley Larkin <sup>1</sup>

**Affiliations**

1. Gastrointestinal Pathogens Unit, National Infection Service, Public Health England, London, United Kingdom
2. Statistics, Modelling and Economics Department, National Infection Service, Public Health England, London, United Kingdom
3. Department of Infectious Disease Epidemiology and NIHR Health Protection Research Unit in Modelling and Health Economics, London School of Hygiene and Tropical Medicine, London, United Kingdom
4. Department of Infection Biology, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom
5. Enteric Virus Unit, National Infection Service Laboratories, Public Health England, London, United Kingdom

**Corresponding author:** Amy Douglas; Address: 61 Colindale Avenue, London, NW1 5EQ, UK; Email: Amy.Douglas@phe.gov.uk

**Running title:** COVID-19 impact on norovirus in England

**Key words:** norovirus; SARS-CoV-2; COVID-19; surveillance; outbreak; epidemic

**Text**

We report a substantial and sustained reduction in norovirus outbreak and norovirus-positive laboratory reports to Public Health England (PHE) since SARS-CoV-2 (COVID-19) control measures were first introduced in 2020. This has raised concerns around the direct and indirect effects of the pandemic on routine surveillance functions, and the need to consider the potential risk of unusual disease activity and novel norovirus strain emergences when such interventions are relaxed.

The observed decrease in norovirus reporting ( $\geq 84.6\%$ , Figure 1) throughout 2020 across all four national surveillance systems used to monitor norovirus activity [1], and the marked decline in referral of norovirus-positive samples for genotyping and monitoring diversity of circulating norovirus strains [1, 2] have limited our ability to perform effective surveillance. These metrics were critical in detecting emerging epidemics during previous norovirus strain replacement events, such as temporally unusual levels of activity seen in the UK during the 2002 summer preceding the 2002/2003 pandemic event [3], or significant changes in the virus genome in the absence of an observed cumulative increase in confirmed norovirus laboratory reports, as was associated with emergence of the GII.4/Sydney strain in England in 2012 [2].

Globally, norovirus strain replacement events over the last 20 years have occurred every 3-4 years [4], with the last recorded in the UK in 2012 [2, 4]. Therefore, it is crucial that molecular surveillance is prioritised in 2021, specifically referral of norovirus-positive samples to the national reference laboratory for molecular characterisation to maximise the opportunity for timely detection of novel noroviruses which could lead to a strain replacement event. Consequently, PHE has updated referral guidance for PHE Regional Public Health and Collaborating Laboratories to include norovirus-positive samples from sporadic cases and outbreak-associated samples in both healthcare and community settings, aiming to highlight the importance of ongoing surveillance and improve the size and representativeness of molecular surveillance.

Changes in healthcare seeking behaviour, disruption to service provision and operational changes in local capacity to detect, test and report norovirus cases or outbreaks due to the COVID-19 pandemic has adversely impacted on norovirus surveillance. However, the reasons for the observed decrease in norovirus reporting are considered multifactorial and the non-pharmaceutical interventions (NPIs) introduced to reduce COVID-19 transmission in England have almost certainly resulted in a true decrease in norovirus transmission; raising the question of what may happen when measures are relaxed.

Similar reductions in norovirus reporting have been observed in other countries including Germany, USA and Australia [1, 5] following implementation of COVID-19 control measures [6]. Furthermore, unusual, delayed temporal peaks in disease activity following relaxation of NPIs have been reported for respiratory syncytial virus in the past [5, 7] and similar disease dynamics may be expected for norovirus whose transmission is facilitated by close social contact. Recent data from Australia support this, where relaxation of COVID-19 NPIs coincided with a sudden increase in gastroenteritis outbreaks in childcare settings reaching a peak in November 2020 [5].

Therefore, anticipating the imminent easing of COVID-19 control measures, we believe there is a real risk of a sudden and rapid increase in norovirus transmission which would result in temporally unusual activity due to:

- an increase in behaviours which facilitate transmission;
- an increased number of susceptible individuals in the population due to low norovirus activity throughout 2020;
- rapid emergence of a norovirus strain with epidemic potential;
- or most likely, a combination of these factors.


Increased or unusual norovirus activity has the potential to overwhelm NHS services [8, 9], especially following the prolonged period of pressure experienced during the COVID-19 pandemic and the substantial number of people awaiting postponed, non-urgent treatments [10]. The paucity of surveillance data on norovirus activity and circulating strains in England during the 2020/2021 winter season means key indicators of a potential strain replacement event are not being monitored as effectively as prior to the emergence of COVID-19 and could leave frontline services insufficiently prepared for any increased 'out-of-season' norovirus activity. Therefore, reporting of outbreaks and submission of norovirus-positive samples to the national reference laboratory is essential to maximise the opportunity to facilitate preparedness planning beyond that of the current COVID-19 pandemic.

## References

- [1] Public Health England [Internet]. National norovirus and rotavirus bulletin: management information 2020 [cited 2021 Feb 15]. Available from: <https://www.gov.uk/government/statistical-data-sets/national-norovirus-and-rotavirus-bulletin-management-information>.
- [2] Allen DJ, Adams NL, Aladin F, Harris JP, Brown DW. Emergence of the GII-4 Norovirus Sydney2012 strain in England, winter 2012-2013. *PloS one*. 2014;9(2):e88978. <https://doi.org/10.1371/journal.pone.0088978>
- [3] Lopman B, Vennema H, Kohli E, Pothier P, Sanchez A, Negredo A, et al. Increase in viral gastroenteritis outbreaks in Europe and epidemic spread of new norovirus variant. *Lancet*. 2004;363(9410):682-8. [https://doi.org/10.1016/s0140-6736\(04\)15641-9](https://doi.org/10.1016/s0140-6736(04)15641-9)
- [4] van Beek J, de Graaf M, Al-Hello H, Allen DJ, Ambert-Balay K, Botteldoorn N, et al. Molecular surveillance of norovirus, 2005-16: an epidemiological analysis of data collected from the NoroNet network. *Lancet Infect Dis*. 2018;18(5):545-53. [https://doi.org/10.1016/s1473-3099\(18\)30059-8](https://doi.org/10.1016/s1473-3099(18)30059-8)
- [5] NSW Government [Internet]. Communicable Disease Weekly Report- weeks 48 and 49, 2020 [cited 2021 Feb 15]. Available from: <https://www.health.nsw.gov.au/Infectious/Reports/Pages/cdwr-2020.aspx>.
- [6] Islam N, Sharp SJ, Chowell G, Shabnam S, Kawachi I, Lacey B, et al. Physical distancing interventions and incidence of coronavirus disease 2019: natural experiment in 149 countries. *BMJ*. 2020;370:m2743. <https://www.bmj.com/content/370/bmj.m2743>
- [7] Lo JY, Tsang TH, Leung YH, Yeung EY, Wu T, Lim WW. Respiratory infections during SARS outbreak, Hong Kong, 2003. *Emerg Infect Dis*. 2005;11(11):1738-41. <https://doi.org/10.3201/eid1111.050729>

- [8] Sandmann FG, Jit M, Robotham JV, Deeny SR. Burden, duration and costs of hospital bed closures due to acute gastroenteritis in England per winter, 2010/11–2015/16. *J Hosp Infect.* 2017;97(1):79-85. <https://doi.org/10.1016/j.jhin.2017.05.015>
- [9] Morder S, Bennet G, Fish J, Richards J, Allen DJ, Nawaz S, et al. Norovirus in the hospital setting: virus introduction and spread within the hospital environment. *J Hosp Infect.* 2011;77(2):106-12.
- [10] Morgan M. Matt Morgan: Head, shoulders, knees, and toes-what's next on the NHS waiting list? *BMJ.* 2021;372:n554. <https://doi.org/10.1136/bmj.n554>

Journal Pre-proof



**Figure title:** *Figure 1.* Decline in norovirus laboratory reports in England (A) and suspected and confirmed norovirus outbreak reports in England by setting (B), 2019/2020 season and weeks 27 to 52 of 2020/2021 season compared to the five-season mean with 95% confidence intervals.

**Figure footnotes:** Data are reported by epidemiological seasons running from week 27 in the first year to week 26 in the second year, capturing the winter peak of activity in one reporting period. Five-season mean and 95% confidence intervals for 2019/20 and 2020/21 seasons are calculated from the 5- season periods of 2014/15 to 2018/19, and 2015/16 to 2019/20, respectively.

Since the first national lockdown in March 2020, multiple areas in England have been subject to variable levels of coronavirus restrictions at the regional level, with a national level 3-tiered restrictions approach first formally implemented in England in October 2020. These data are derived from three of PHE's national surveillance systems (described [here](#)).

**Acknowledgements:** The authors would like to thank all NHS and PHE staff who report national norovirus surveillance data; including NHS Infection Prevention and Control staff (Hospital Norovirus Outbreak Reporting System users), PHE local (Health Protection Teams) and PHE regional teams (Field Services) and PHE Regional Public Health and Collaborating Laboratories.

**Conflict of interest:** None declared.

**Funding statement:** This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. This work was supported by Public Health England (PHE), which is an executive agency of the Department of Health and Social Care (DHSC). The authors had sole responsibility for the study design, data collection, data analysis, data interpretation, and writing. FGS was partly supported by the NIHR HPRU in Modelling and Health Economics, a partnership between PHE, Imperial College London and LSHTM [grant code NIHR200908]. This work was supported by the Wellcome Trust [grant code 203268/Z/16/Z]. The views expressed are those of the authors and not necessarily those of DHSC, NHS, NIHR, or PHE.

**Authors' contributions:** AD, FGS, DA, and LL conceived the study. FGS and AD wrote the first draft of the manuscript with feedback from all other authors including CC and SB. All authors contributed to the interpretation of the data and findings, contributed to the manuscript, and approved the work for publication.

